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A Caucasian male was delivered vaginally (gestational ge: 
26 weeks; weight 825 g) and showed signs of respiratory insuffi- 
ciency, necessitating artificial ventilation for 39 days. On the 
10th day after birth he developed a maculopapular rash which 
became scaly and later pustular. There were no signs of pulmo- 
nary infection or other organ involvement. After 1 week, cul- 
tures of the pustutar cutaneous lesions yielded A.fumigatus. 
Histology with visualization of hyphae was not performed. 
Bacterial and viral cultures of blood, urine, skin, sputum and 
the conjuctival swab were sterile. Serologically, concomitant 
virus infections were not demonstrated. At that moment oph- 
thalmological examination was not performed. The primary 
skin lesions were treated locally. Broad spectrum antibiotics 
(flucloxacillin and amoxicillin) were added when pustular le- 
sions developed. After 3 days with broad spectrum antibiotics 
his clinical condition deteriorated and antifungal treatment 
(amphotericin B and flucytosine) were started. There was a 
gradual clinical improvement and the skin lesions healed, indi- 
rectly supporting the clinical diagnosis of Aspergillus disease. 
After 4 weeks, intravenous amphotericin B therapy was stop- 
ped, without signs of recurrence. Three weeks later during 
routine ophthalmological examination for retinopathy of pre- 
maturity, haziness of the media was seen. Ultrasonography of 
the eyes showed irregularities of the retina. Vitrectomy was 
performed and showed a distorted retina with microabscesses. 
The pus obtained from the vitreous cavity and retinal micro- 
abscesses showed no bacterial or fungal growth. Again histo- 
logical sections were not performed. Thus possible fungal ele- 
ments could not be looked for. Despite these negative findings 
a presumptive diagnosis of Aspergillus endophthalmitis was 
made based on the history of the skin lesions with positive cul- 
tures of Aspergillus, which healed with systemic antifungal 
treatment, and the known poor intraocular penetration of am- 
photericin B [3]. The subsequent clinical course was compli- 
cated by a patent ductus arteriosus, bronchopulmonary d s- 
plasia and intracranial haemorrhage. 
This case shows that in the preterm neonate with a severe 
or an expanding skin lesion the presence of A.fumigatus 
should be considered. To prove the diagnosis histology is oblig- 
atory. Ophthalmological examinations should be performed in 
preterm infants with suspected fungal infection in order to de- 
tect possible fungal endophthalmitis. 
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Sir: Neonatal bacterial sepsis is associated with a high risk of 
mortality and morbidity, especially in preterm infants. 
Vancomycin therapy is usually started when septicaemia, 
presumed to be caused by multiple resistant Staphyloccus epi- 
dermidis, is suspected. At present, there are no data available 
concerning possible side-effects of vancomycin in the prema- 
ture neonate, related to serum concentrations. Nephrotoxic 
and ototoxic side-effects are reported in older children. Oto- 
toxicity is reportedly caused by damage to the sensory cilia in 
the cochlea nd is irreversible. It has been observed with serum 
concentrations of 80-100mg/1 [1, 2]. The nephrotoxic side- 
effects in older children are reported to be reversible and re- 
lated to serum levels > 40 mg/1; the incidence is unknown [1, 3, 
4]. We here describe acute vancomycin intoxication in a pre- 
mature neonate. 
A caucasian female was born at a gestational ge of 29.3 
weeks, weighing 1520 g. In the 4th week of life septicaemia was 
suspected. Tobramycin (2.5 mg/kg every 18 h) and vancomycin 
(15mg/kg every 12h according to the regimen suggested by 
Schaad et al.) were started [5]. Blood cultures grew S. epi- 
dermidis. Twenty-four hours after the start of therapy the child 
became oliguric and serum creatinine doubled from 41 to 86 
~tmolfl. Antibiotics were immediately discontinued. Serum 
vancomycin concentration was elevated (63.3mg/1 12h after 
becoming oliguric) while tobramycin concentration was normal 
(1.8 mg/1); so we concluded that the renal failure was second- 
ary to vancomycin toxicity. The course of the serum concentra- 
tions of vancomycin and creatinine are shown in Fig. 1. During 
the episode of elevated serum vancomycin concentration no 
further clinical or biochemical abnormalities were noted. 
Repeated brainstem evoked auditory potentials showed no co- 
chlear hearing impairment. Two months after the event, no 
nephrological abnormalities were demonstrated either 
biochemically or by ultrasonography. 
This case suggests that vancomycin overdosage can produce 
reversible renal impairment in preterm neonates. Creatinine 
concentration and drug levels should be carefully monitored. If
oliguria is observed vancomycin should be immediately with- 
drawn until serum creatinine and drug concentration are avail- 
able. 
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